<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>XLY.TO</title>
  <style>
    /* Default styles provided by pandoc.
    ** See https://pandoc.org/MANUAL.html#variables-for-html for config info.
    */
    html {
      color: #1a1a1a;
      background-color: #fdfdfd;
    }
    body {
      margin: 0 auto;
      max-width: 36em;
      padding-left: 50px;
      padding-right: 50px;
      padding-top: 50px;
      padding-bottom: 50px;
      hyphens: auto;
      overflow-wrap: break-word;
      text-rendering: optimizeLegibility;
      font-kerning: normal;
    }
    @media (max-width: 600px) {
      body {
        font-size: 0.9em;
        padding: 12px;
      }
      h1 {
        font-size: 1.8em;
      }
    }
    @media print {
      html {
        background-color: white;
      }
      body {
        background-color: transparent;
        color: black;
        font-size: 12pt;
      }
      p, h2, h3 {
        orphans: 3;
        widows: 3;
      }
      h2, h3, h4 {
        page-break-after: avoid;
      }
    }
    p {
      margin: 1em 0;
    }
    a {
      color: #1a1a1a;
    }
    a:visited {
      color: #1a1a1a;
    }
    img {
      max-width: 100%;
    }
    svg {
      height: auto;
      max-width: 100%;
    }
    h1, h2, h3, h4, h5, h6 {
      margin-top: 1.4em;
    }
    h5, h6 {
      font-size: 1em;
      font-style: italic;
    }
    h6 {
      font-weight: normal;
    }
    ol, ul {
      padding-left: 1.7em;
      margin-top: 1em;
    }
    li > ol, li > ul {
      margin-top: 0;
    }
    blockquote {
      margin: 1em 0 1em 1.7em;
      padding-left: 1em;
      border-left: 2px solid #e6e6e6;
      color: #606060;
    }
    code {
      font-family: Menlo, Monaco, Consolas, 'Lucida Console', monospace;
      font-size: 85%;
      margin: 0;
      hyphens: manual;
    }
    pre {
      margin: 1em 0;
      overflow: auto;
    }
    pre code {
      padding: 0;
      overflow: visible;
      overflow-wrap: normal;
    }
    .sourceCode {
     background-color: transparent;
     overflow: visible;
    }
    hr {
      border: none;
      border-top: 1px solid #1a1a1a;
      height: 1px;
      margin: 1em 0;
    }
    table {
      margin: 1em 0;
      border-collapse: collapse;
      width: 100%;
      overflow-x: auto;
      display: block;
      font-variant-numeric: lining-nums tabular-nums;
    }
    table caption {
      margin-bottom: 0.75em;
    }
    tbody {
      margin-top: 0.5em;
      border-top: 1px solid #1a1a1a;
      border-bottom: 1px solid #1a1a1a;
    }
    th {
      border-top: 1px solid #1a1a1a;
      padding: 0.25em 0.5em 0.25em 0.5em;
    }
    td {
      padding: 0.125em 0.5em 0.25em 0.5em;
    }
    header {
      margin-bottom: 4em;
      text-align: center;
    }
    #TOC li {
      list-style: none;
    }
    #TOC ul {
      padding-left: 1.3em;
    }
    #TOC > ul {
      padding-left: 0;
    }
    #TOC a:not(:hover) {
      text-decoration: none;
    }
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    /* The extra [class] is a hack that increases specificity enough to
       override a similar rule in reveal.js */
    ul.task-list[class]{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      font-size: inherit;
      width: 0.8em;
      margin: 0 0.8em 0.2em -1.6em;
      vertical-align: middle;
    }
    .display.math{display: block; text-align: center; margin: 0.5rem auto;}
  </style>
</head>
<body>
<h1 id="auxly-cannabis-group-inc.">Auxly Cannabis Group Inc.</h1>
<h2 id="business-summary">Business summary</h2>
<ul>
<li>Canadian cannabis CPG company focused on branded dried flower,
vapes, and pre-rolls; ranked 3rd by total rec retail sales in Q2 2025
(Hifyre IQ).</li>
<li>Vertically integrated with cultivation and processing at Auxly
Leamington (1.1M sq. ft. greenhouse) and product development/processing
at GMP-compliant Auxly Charlottetown.</li>
<li>National distribution across all provinces and territories; mix
includes Cannabis 1.0 and 2.0 products, plus selective wholesale bulk
cannabis.</li>
<li>Strategy centers on consumer insight–driven innovation, operational
efficiency, and disciplined capital allocation to drive profitable
growth and margin expansion.</li>
</ul>
<h2 id="recent-developments">Recent developments</h2>
<ul>
<li>Amended and extended credit facility with BMO-led syndicate (July 7,
2025): Auxly became the borrower, added a $10M revolver, maturity
extended to June 30, 2027 (one-year extension option), and covenants
revised; security expanded to all company assets.</li>
<li>Settled Imperial Brands convertible debenture (July 7, 2025):
converted remaining principal and a portion of accrued interest into
shares; issued pre-funded warrants for additional interest; remaining
~$11.9M interest forgiven; no further amounts owed to Imperial.</li>
<li>Repaid inventory/receivables financing loan in full (July 7,
2025).</li>
<li>AGM outcomes (June 30, 2025): all matters approved as announced July
2, 2025.</li>
</ul>
<h2 id="key-issues">Key issues</h2>
<ul>
<li>Execution on growth with margin discipline: sustaining improved
gross margin on finished cannabis inventory sold (51–52% YTD/Q2) while
funding higher selling expenses to support volume.</li>
<li>Liquidity and leverage management: maintaining covenant compliance
under the amended credit facility and prudent use of the new $10M
revolver; managing ~$49M debt and lease obligations.</li>
<li>Market dynamics and pricing: exposure to excise taxes, potential
price compression, and competitive intensity across flower, pre-rolls,
and vapes.</li>
<li>Share count overhang/dilution: large base of outstanding/issuable
equity (RSUs, options, warrants, and Imperial pre-funded warrants capped
by 19.9% ownership) may impact per-share metrics.</li>
<li>Regulatory and accounting volatility: fair value adjustments
(biological assets/inventory), evolving cannabis regulations, and prior
audit going concern qualification–related reporting covenant waiver
underscore the need for consistent performance.</li>
<li>Concentration and expansion: heavy reliance on Canadian adult-use
channels (BC/AB/ON ~75% of sales); international sales are exploratory
and not yet a material contributor.</li>
</ul>
<h2 id="auxly-cannabis-group-inc.-selected-financials">Auxly Cannabis
Group Inc. — Selected Financials</h2>
<table>
<colgroup>
<col style="width: 56%" />
<col style="width: 10%" />
<col style="width: 10%" />
<col style="width: 10%" />
<col style="width: 10%" />
</colgroup>
<thead>
<tr>
<th>Metric (CAD ‘000s, except percentages)</th>
<th style="text-align: right;">Q2 2025</th>
<th style="text-align: right;">Q2 2024</th>
<th style="text-align: right;">H1 2025</th>
<th style="text-align: right;">H1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net revenues</td>
<td style="text-align: right;">38,802</td>
<td style="text-align: right;">29,178</td>
<td style="text-align: right;">71,471</td>
<td style="text-align: right;">54,419</td>
</tr>
<tr>
<td>Gross profit</td>
<td style="text-align: right;">22,689</td>
<td style="text-align: right;">15,929</td>
<td style="text-align: right;">41,372</td>
<td style="text-align: right;">25,380</td>
</tr>
<tr>
<td>Operating income (loss)</td>
<td style="text-align: right;">8,140</td>
<td style="text-align: right;">2,101</td>
<td style="text-align: right;">12,203</td>
<td style="text-align: right;">(7,094)</td>
</tr>
<tr>
<td>EBITDA</td>
<td style="text-align: right;">13,205</td>
<td style="text-align: right;">7,458</td>
<td style="text-align: right;">21,861</td>
<td style="text-align: right;">6,809</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td style="text-align: right;">11,545</td>
<td style="text-align: right;">5,173</td>
<td style="text-align: right;">18,978</td>
<td style="text-align: right;">7,413</td>
</tr>
<tr>
<td>Net income (loss)</td>
<td style="text-align: right;">8,310</td>
<td style="text-align: right;">2,002</td>
<td style="text-align: right;">20,421</td>
<td style="text-align: right;">(24,010)</td>
</tr>
<tr>
<td>Cash flow from operations</td>
<td style="text-align: right;">3,632</td>
<td style="text-align: right;">2,927</td>
<td style="text-align: right;">5,601</td>
<td style="text-align: right;">693</td>
</tr>
<tr>
<td>Capital expenditures</td>
<td style="text-align: right;">(223)</td>
<td style="text-align: right;">(1,040)</td>
<td style="text-align: right;">(290)</td>
<td style="text-align: right;">(1,345)</td>
</tr>
<tr>
<td>Gross Profit Margin (%)</td>
<td style="text-align: right;">58%</td>
<td style="text-align: right;">55%</td>
<td style="text-align: right;">58%</td>
<td style="text-align: right;">47%</td>
</tr>
<tr>
<td>Gross Margin on Finished Inventory Sold (%)</td>
<td style="text-align: right;">52%</td>
<td style="text-align: right;">41%</td>
<td style="text-align: right;">51%</td>
<td style="text-align: right;">40%</td>
</tr>
</tbody>
</table>
<p>Notes:</p>
<ul>
<li>Operating income = Gross profit − Total expenses (excludes “Other
income/loss” and taxes).</li>
<li>EBITDA and Adjusted EBITDA per company reconciliation; H1 figures
derived by summing quarterly amounts where applicable.</li>
<li>Margins as disclosed: Gross Profit Margin = gross profit/net
revenues; “Gross Margin on Finished Inventory Sold” excludes FV changes
and impairments.</li>
</ul>
<h2 id="capitalization-cash-debt-and-enterprise-value">Capitalization,
Cash, Debt, and Enterprise Value</h2>
<p>Assumptions and sources:</p>
<ul>
<li>Stock price assumed at CAD $0.145.</li>
<li>Share counts from MD&amp;A: Outstanding shares and exercisable
securities as of June 30, 2025 and August 13, 2025.</li>
<li>Fully diluted assumes all RSUs, options, and warrants (including
Imperial pre-funded warrants) are exercised; treasury method and
exercise prices not disclosed, so dilution is presented on a gross
basis. Imperial pre-funded warrants are capped at 19.9% ownership until
expiry; included here for illustrative FD count.</li>
<li>Cash (CAD $17.0m) and Debt (CAD $49.0m) as of June 30, 2025 per
MD&amp;A. Post-quarter items: Imperial debenture fully settled;
inventory/receivables financing loan repaid (amount not disclosed); new
$10m revolver availability (undrawn amount not disclosed).</li>
</ul>
<table>
<colgroup>
<col style="width: 8%" />
<col style="width: 36%" />
<col style="width: 54%" />
</colgroup>
<thead>
<tr>
<th>Item</th>
<th style="text-align: right;">Q2 2025 (Jun 30)</th>
<th style="text-align: right;">Pro forma (Aug 13, 2025)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Price (CAD)</td>
<td style="text-align: right;">$0.145</td>
<td style="text-align: right;">$0.145</td>
</tr>
<tr>
<td>Basic Shares Outstanding</td>
<td style="text-align: right;">1,316,298,654</td>
<td style="text-align: right;">1,342,272,643</td>
</tr>
<tr>
<td>Warrants</td>
<td style="text-align: right;">80,039,000</td>
<td style="text-align: right;">163,285,118</td>
</tr>
<tr>
<td>Options</td>
<td style="text-align: right;">15,681,169</td>
<td style="text-align: right;">15,681,169</td>
</tr>
<tr>
<td>RSUs</td>
<td style="text-align: right;">158,096,425</td>
<td style="text-align: right;">158,096,425</td>
</tr>
<tr>
<td>Convertible Debentures (as-converted shares)</td>
<td style="text-align: right;">1,234,568</td>
<td style="text-align: right;">— (settled)</td>
</tr>
<tr>
<td>Fully Diluted Shares (gross)</td>
<td style="text-align: right;">1,571,349,816</td>
<td style="text-align: right;">1,679,335,355</td>
</tr>
<tr>
<td>Implied Market Cap (Basic)</td>
<td style="text-align: right;">$190.9m</td>
<td style="text-align: right;">$194.6m</td>
</tr>
<tr>
<td>Implied Market Cap (Fully Diluted)</td>
<td style="text-align: right;">$227.8m</td>
<td style="text-align: right;">$243.5m</td>
</tr>
<tr>
<td>Cash</td>
<td style="text-align: right;">$17.0m</td>
<td style="text-align: right;">$17.0m (PF not adjusted; cash impact of
post-Q2 repayments not disclosed)</td>
</tr>
<tr>
<td>Debt (per company “Debt” measure)</td>
<td style="text-align: right;">$49.0m</td>
<td style="text-align: right;">$49.0m (PF to decline for repaid
inventory financing; amount not disclosed)</td>
</tr>
<tr>
<td>Enterprise Value (Basic)</td>
<td style="text-align: right;">$222.8m</td>
<td style="text-align: right;">$226.6m (PF uses same cash/debt pending
disclosure)</td>
</tr>
<tr>
<td>Enterprise Value (Fully Diluted)</td>
<td style="text-align: right;">$259.8m</td>
<td style="text-align: right;">$275.5m (PF uses same cash/debt pending
disclosure)</td>
</tr>
<tr>
<td>Notable PF adjustments</td>
<td style="text-align: right;">—</td>
<td style="text-align: right;">Imperial debenture fully settled;
inventory financing loan repaid; $10m revolver available</td>
</tr>
</tbody>
</table>
<p>Notes:</p>
<ul>
<li>Pro forma share counts reflect post-quarter issuances, including
18.34m shares to Imperial and 90.88m pre-funded warrants issued July 7,
2025. The pre-funded warrants are exercisable at a nominal price but
subject to a 19.9% ownership cap.</li>
<li>Actual pro forma EV will be lower than shown once the repayment of
the inventory/receivables financing loan is quantified (debt reduced by
the repaid amount) and any cash changes are reflected.</li>
</ul>
<h2 id="valuation">Valuation</h2>
<p>Assumptions and sources:</p>
<ul>
<li>All figures in CAD. FY2024 EBITDA and quarterly EBITDA/Adjusted
EBITDA from the company’s MD&amp;A reconciliation table; 2025 Q2 and H1
metrics from the provided markdown “Selected Financials.”</li>
<li>LTM is calculated as: FY2024 + H1 2025 − H1 2024.</li>
<li>Enterprise Value (EV) uses Q2 2025 values from the provided table:
EV (Basic) $222.8m; EV (Fully Diluted) $259.8m.</li>
</ul>
<table>
<thead>
<tr>
<th>Item</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2024 EBITDA</td>
<td>$24.7m</td>
</tr>
<tr>
<td>Add: H1 2025 EBITDA</td>
<td>$21.9m</td>
</tr>
<tr>
<td>Minus: H1 2024 EBITDA</td>
<td>$6.8m</td>
</tr>
<tr>
<td>LTM EBITDA (Q2 2025)</td>
<td>$39.8m</td>
</tr>
<tr>
<td>FY 2024 Adjusted EBITDA</td>
<td>$26.7m</td>
</tr>
<tr>
<td>Add: H1 2025 Adjusted EBITDA</td>
<td>$19.0m</td>
</tr>
<tr>
<td>Minus: H1 2024 Adjusted EBITDA</td>
<td>$7.4m</td>
</tr>
<tr>
<td>LTM Adjusted EBITDA (Q2 2025)</td>
<td>$38.3m</td>
</tr>
<tr>
<td>EV (Basic)</td>
<td>$222.8m</td>
</tr>
<tr>
<td>EV (Fully Diluted)</td>
<td>$259.8m</td>
</tr>
<tr>
<td>EV/EBITDA (Basic)</td>
<td>5.6x</td>
</tr>
<tr>
<td>EV/EBITDA (Fully Diluted)</td>
<td>6.5x</td>
</tr>
<tr>
<td>EV/Adj. EBITDA (Basic)</td>
<td>5.8x</td>
</tr>
<tr>
<td>EV/Adj. EBITDA (Fully Diluted)</td>
<td>6.8x</td>
</tr>
</tbody>
</table>
<p>Notes: - EV figures are as of Q2 2025 and do not reflect subsequent
pro forma debt reductions or cash changes post-quarter.</p>
</body>
</html>
